Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18469476 | 0.84 | ALDH1A1 (0.44) | MAOBALDH1A1MAPTHTTCYP1A2 | |
| SCHEMBL28128651 | 0.82 | MAOB (0.47) | MAOBALDH1A1CA12CA1CA2 | |
| SCHEMBL10173405 | 0.80 | ADAM17 (0.43) | ALDH1A1MAPT | |
| SCHEMBL13923566 | 0.78 | MAOB (0.50) | MAOBALDH1A1CA12CA1CA2 | |
| SCHEMBL21010771 | 0.78 | ALDH1A1 (0.35) | ALDH1A1CA12CA1CA9MAPT | |
| SCHEMBL4790661 | 0.78 | CA12 (0.46) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL25159374 | 0.76 | STS (0.35) | CA12CA1CA2CA9MAPT | |
| SCHEMBL13923568 | 0.76 | CYP2A6 (0.53) | MAOBALDH1A1CA12CA1CA2 | |
| SCHEMBL23172755 | 0.76 | APP (0.43) | ALDH1A1 | |
| SCHEMBL10222547 | 0.76 | CYP1A2 (0.41) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-7989472-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAOB 4060/4885ALDH1A1 1445/4885CA12 3638/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAOB 4060/4885ALDH1A1 1445/4885CA12 3638/4885 |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OTC, OCIAD1 | MAOB 389/4885ALDH1A1 423/4885CA12 4687/4885 |
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | MAOB 1556/4885ALDH1A1 4169/4885CA12 1351/4885 |
| US-20150005287-A2 | QUINOLONE COMPOUND | HAX1, NQO2, VIP | MAOB 4197/4885ALDH1A1 1492/4885CA12 3630/4885 |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | MAOB 1677/4885ALDH1A1 4625/4885CA12 1857/4885 |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MAOB 25/4885ALDH1A1 102/4885CA12 4841/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | MAOB 1803/4885ALDH1A1 4297/4885CA12 1913/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAOB 4037/4885ALDH1A1 1466/4885CA12 3657/4885 |
| US-20140179675-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAOB 4060/4885ALDH1A1 1445/4885CA12 3638/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | MAOB 3978/4885ALDH1A1 1573/4885CA12 3803/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | MAOB 197/4885ALDH1A1 461/4885CA12 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.